Oppenheimer Reiterates Outperform on Ascendis Pharma, Raises Price Target to $190
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Leland Gershell has reiterated an Outperform rating on Ascendis Pharma (NASDAQ:ASND) and increased the price target from $180 to $190.
September 17, 2024 | 1:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer has reiterated its Outperform rating on Ascendis Pharma and increased the price target from $180 to $190, indicating confidence in the company's future performance.
The reiteration of an Outperform rating and an increased price target by a reputable analyst can positively influence investor sentiment and potentially lead to a short-term increase in ASND's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100